SPOTLIGHT: Novartis wins OK for cell-based flu vaccine

Novartis has received EU approval for its new flu vaccine, Optaflu. The approval puts the pharma giant on track for the first launch of a cell-based flu vaccine. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.